EXPERIENCE WITH THE USE OF PIOGLITAZONE FOR THE PREVENTION AND TREATMENT OF EXPERIMENTAL URATE NEPHROLITHIASIS
https://doi.org/10.24884/1561-6274-2017-21-1-52-56
Abstract
THE AIM. To assess the effectiveness of selective agonist of PPAR gamma receptors (Peroxisome Proliferator-Activated Receptor) pioglitazone, as a drug of prevention and treatment of experimental urate nephropathy. MATERIAL AND METHODS. The study was conducted on 37 male rats Wistar stock. For the formation of urate nephropathy in rats inhibited uricase by co-administration of uric acid and oxonium. For the prevention and treatment of experimental pathology animals received pioglitazone. On day 21 using biochemical and morphological techniques were evaluated received changes. RESULTS. In the experimental condition were observed significant decrease of urate stones in kidneys, significant decrease of uric acid in blood plasma and urine of rats, increase of the urine pH, increase of glomerular filtration rate and inhibition processes of free radical oxidation in the blood of animals. CONCLUSION. Long-term use of pioglitazone in the preventive and therapeutic modes, significantly improves the experimental urate nephrolithiasis.
About the Authors
V. Y. Perfiliev
Altai State Medical University
Russian Federation
Russian Federation
Perfilev Y. Vyacheslav
Department of Pharmacology.
656038, Russia, Barnaul, Lenin Avenue 40
Y. F. Zverev
Altai State Medical University
Russian Federation
Russian Federation
Prof. Yakov F. Zverev DMedSci.
Department of Pharmacology.
656038, Russia, Barnaul, Lenin Avenue 40
A. Y. Zharikov
Altai State Medical University
Russian Federation
Russian Federation
Prof. Alexander Yu. Zharikov DBiolSci
Department of Pharmacology.
656038, Russia, Barnaul, Lenin Avenue 40
D. Y. Lukiyanenko
Altai State Medical University
Russian Federation
5th year students of medical – prophylactic faculty
Russian Federation
5th year students of medical – prophylactic faculty
I. V. Lysenko
Altai State Medical University
Russian Federation
6th year students of medical faculty
Russian Federation
6th year students of medical faculty
O. S. Atabaeva
Altai State Medical University
Russian Federation
Russian Federation
Atabaeva O.Sh. СBiolSci
Department of Pharmacology.
656038, Russia, Barnaul, Lenin Avenue 40
References
1. Калашникова МФ. Метаболический синдром: современный взгляд на концепцию, методы профилактики и лечения. Эффективная фармакотерапия 2013; 52: 52-63 [Kalashnikova MF. Metabolicheskij sindrom: sovremennyj vzgljad na koncepciju, metody profilaktiki i lechenija. Jeffektivnaja farmakoterapija. 2013; 52: 52-63]
2. Kim Y-J, Kim C-H, Sung E-J et al. Association of nephrolithiasis with metabolic syndrome and its components. Metabolism 2013; 62 (6): 808-813
3. Антипова ВН, Казеева МВ. Кардиоваскулярный риск и метаболический синдром у больных подагрой. Изв высших учебных заведений. Поволжский регион. Мед науки 2015; 1 (33): 112-122 [Antipova VN, Kazeeva MV. Kardiovaskuljarnyj risk i metabolicheskij sindrom u bol’nyh podagroj. Izvestija vysshih uchebnyh zavedenij. Povolzhskij region. Medicinskie nauki 2015; 1 (33): 112-122]
4. Бокарев ИН. Метаболический синдром. Клин мед 2014; 92 (8): 71-76 [Bokarev IN. Metabolicheskij sindrom. Klinicheskaja medicina 2014; 92 (8): 71-76]
5. Барскова ВГ, Елисеев МС, Денисов ИС и др. Частота метаболического синдрома и сопутствующих заболеваний у больных подагрой. Данные многоцентрового исследования Науч-практ ревматол 2012; 50 (6): 15-18 [Barskova VG, Eliseev MS, Denisov IS i dr. Chastota metabolicheskogo sindroma i soputstvujushhih zabolevanij u bol'nyh podagroj. Dannye mnogocentrovogo issledovanija Nauchno-prakticheskaja revmatologija. 2012; 50 (6): 15-18]
6. Akman T, Binbay M, Erbin A et al. The impact of metabolic syndrome on long-term outcomes of percutaneous nephrolithotomy (PCNL). BJU Int 2012; 110: E1079-E1083
7. Bobulescu IA, Maalouf NM, Capolongo G et al. Renal ammonium excretion after an acute acid load: blunted response in uric acid stone formers but not in patients with type 2 diabetes. Am J Physiol Renal Physiol 2013; 305: E1498-E1503
8. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004; 55 (6): 3145–3152
9. Sakhaee K, Maalouf NM. Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol 2008; 28 (2): 174-180
10. Abate N, Chandalia M, Cabo-Chan AV Jr et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004; 65: 386-392
11. Cameron MA, Maalouf NM, Adams-Huet B et al. Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol 2006; 17: 1422-1428
12. Перфильев ВЮ, Зверев ЯФ, Брюханов ВМ и др. Успешный опыт моделирования уратной нефропатии у крыс. Нефрология 2016; 4 (20): 93-97 [Perfil’ev VJu, Zverev JaF, Brjuhanov VM i dr. Uspeshnyj opyt modelirovanija uratnoj nefropatii u krys. Nefrologija 2016; 4 (20): 93-97]
13. Curthoys NP. Renal ammonium ion production and excretion. In: Alpern RJ, Caplan M, Moe OW eds. Seldin and Giebisch’s The Kidney Physiology and Pathophysiology (5th ed.). San Diego, CA: Academic Press, 2013; 1995-2019
14. Nissim I, States B, Nissim I et al. Hormonal regulation of glutamine metabolism by OK cells. Kidney Int 1995; (47) 96-105
15. Schulz E, Gori T, Münzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res 2011; 34: 665-673
16. Glantzounis GK, Tsimoyiannis EC, Kappas AM et al. Uric acid and oxidative stress. Curr Pharm Des 2005; 32, 11: 4145-4151
17. Титов ВН, Дмитриев ВА, Гущина ОВ и др. Физикохимическая активность мочевой кислоты. Гиперурикемия – нарушение биологических функций эндоэкологии и адаптации, биологических реакций экскреции, воспаления и гидродинамического артериального давления. Успехи совр биол 2011; 131 (5): 483-502 [Titov VN, Dmitriev VA, Gushhina OV i dr. Fiziko-himicheskaja aktivnost’ mochevoj kisloty. Giperurikemija – narushenie biologicheskih funkcij jendojekologii i adaptacii, biologicheskih reakcij jekskrecii, vospalenija i gidrodinamicheskogo arterial’nogo davlenija. Uspehi sovr biol 2011; 131 (5): 483-502]
18. Parman M.S. Uric acid and cardiovascular risk. N Engl J Med 2009; 360: 539
Review
For citations:
Perfiliev V.Y., Zverev Y.F., Zharikov A.Y., Lukiyanenko D.Y., Lysenko I.V., Atabaeva O.S. EXPERIENCE WITH THE USE OF PIOGLITAZONE FOR THE PREVENTION AND TREATMENT OF EXPERIMENTAL URATE NEPHROLITHIASIS. Nephrology (Saint-Petersburg). 2017;21(1):52-56. (In Russ.) https://doi.org/10.24884/1561-6274-2017-21-1-52-56
Views:
823
Email this article 